NASDAQ:ALXO ALX Oncology Q1 2025 Earnings Results & Report $1.02 -0.06 (-5.56%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more. ALX Oncology missed analyst earnings expectations in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$0.58 versus the -$0.47 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 8, 2025TimeBefore Market OpensConference Call7:00 AM ET ALX Oncology EPS ResultsActual EPS-$0.58Consensus EPS -$0.47Beat/MissMissed by -$0.11One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersALX Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsALX Oncology's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ALX Oncology Q1 2025 Earnings FAQ Did ALX Oncology beat earnings estimates for Q1 2025? ALX Oncology (NASDAQ:ALXO) reported earnings of -$0.58 per share for Q1 2025, missing the consensus estimate of -$0.47. The report was announced on Thursday, May 8, 2025. When is ALX Oncology's next earnings date? ALX Oncology's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for ALX Oncology on the company's earnings history page. ALX Oncology Earnings HeadlinesAnalysts Are Bullish on These Healthcare Stocks: ALX Oncology Holdings (ALXO), United Therapeutics (UTHR)October 21, 2026 | theglobeandmail.comAlx Oncology Holdings (ALXO)September 30, 2026 | in.investing.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 13 at 1:00 AM | Base Camp Trading (Ad)ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2 ...September 28, 2026 | finance.yahoo.comAlx Oncology Holdings Inc. Announces Nature Medicine Publication of Aspen-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept ...September 28, 2026 | marketscreener.comMALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerSeptember 28, 2026 | globenewswire.comSee More ALX Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALX Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALX Oncology and other key companies, straight to your email. Email Address About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its research centers on the CD47 immune checkpoint, a signal that can help cancer cells evade the immune system. The company’s lead candidate, evorpacept (also known as ALX148), is an investigational CD47-blocking protein designed to support the immune system’s ability to recognize and attack cancer cells. ALX Oncology has studied evorpacept in combination with other cancer treatments across several tumor types. Based in South San Francisco, California, ALX Oncology advances its candidates through clinical development and evaluates them in trials conducted in collaboration with research centers and clinical partners.View ALX Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
